Literature DB >> 21644263

Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling.

Wei-Chun HuangFu, Juan Qian, Chengbao Liu, Hallgeir Rui, Serge Y Fuchs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21644263      PMCID： PMC3688261          DOI： 10.1111/j.1755-148x.2010.00770.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  11 in total

Review 1.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

Review 2.  Negative regulation of type I interferon signaling: facts and mechanisms.

Authors:  E M Coccia; G Uzé; S Pellegrini
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2006-05-15       Impact factor: 1.770

Review 3.  Autocrine and paracrine roles for growth factors in melanoma.

Authors:  I M Shih; M Herlyn
Journal:  In Vivo       Date:  1994 Jan-Feb       Impact factor: 2.155

4.  Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells.

Authors:  K G Suresh Kumar; Jianghuai Liu; Ying Li; Duonan Yu; Andrei Thomas-Tikhonenko; Meenhard Herlyn; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2007-06-13       Impact factor: 4.742

5.  Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor.

Authors:  K G Suresh Kumar; John J Krolewski; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2004-08-26       Impact factor: 5.157

6.  Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor.

Authors:  Sabyasachi Bhattacharya; Wei-Chun HuangFu; Jianghuai Liu; Sudhakar Veeranki; Darren P Baker; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2009-11-30       Impact factor: 5.157

7.  Activated stat-3 in melanoma.

Authors:  Jane L Messina; Hua Yu; Adam I Riker; Pamela N Munster; Richard L Jove; Adil I Daud
Journal:  Cancer Control       Date:  2008-07       Impact factor: 3.302

8.  SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor.

Authors:  K G Suresh Kumar; Weigang Tang; Abhilash K Ravindranath; William A Clark; Ed Croze; Serge Y Fuchs
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

9.  Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling.

Authors:  Vladimir S Spiegelman; Weigang Tang; Andrew M Chan; Makoto Igarashi; Stuart A Aaronson; David A Sassoon; Masaru Katoh; Thomas J Slaga; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2002-07-31       Impact factor: 5.157

Review 10.  Adjuvant therapy of melanoma with interferon: lessons of the past decade.

Authors:  Paolo A Ascierto; John M Kirkwood
Journal:  J Transl Med       Date:  2008-10-27       Impact factor: 5.531
View more
  8 in total

Review 1.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

2.  Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications.

Authors:  Partha Ray; Bruce A Sullenger; Rebekah R White
Journal:  Nucleic Acid Ther       Date:  2013-10-23       Impact factor: 5.486

3.  Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.

Authors:  Christopher J Carbone; Hui Zheng; Sabyasachi Bhattacharya; John R Lewis; Alexander M Reiter; Paula Henthorn; Zhong-Yin Zhang; Darren P Baker; Radha Ukkiramapandian; Kendra K Bence; Serge Y Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-05       Impact factor: 11.205

4.  A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon.

Authors:  Kang-Jian Zhang; Xiao-Fei Yin; Yuan-Qin Yang; Hui-Ling Li; Yan-Ni Xu; Lie-Yang Chen; Xi-Jun Liu; Su-Jing Yuan; Xian-Long Fang; Jing Xiao; Shuai Wu; Hai-Neng Xu; Liang Chu; Kanstantsin V Katlinski; Yuliya V Katlinskaya; Rong-Bing Guo; Guang-Wen Wei; Da-Cheng Wang; Xin-Yuan Liu; Serge Y Fuchs
Journal:  Clin Cancer Res       Date:  2016-09-28       Impact factor: 12.531

Review 5.  Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.

Authors:  Serge Y Fuchs
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

Review 6.  Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer.

Authors:  Angélica Ortiz; Serge Y Fuchs
Journal:  Cytokine       Date:  2016-01-25       Impact factor: 3.861

7.  Inflammatory signaling compromises cell responses to interferon alpha.

Authors:  W-C Huangfu; J Qian; C Liu; J Liu; A E Lokshin; D P Baker; H Rui; S Y Fuchs
Journal:  Oncogene       Date:  2011-06-13       Impact factor: 9.867

8.  Regulation of interleukin-10 receptor ubiquitination and stability by beta-TrCP-containing ubiquitin E3 ligase.

Authors:  Hui Jiang; Yi Lu; Liang Yuan; Jianghuai Liu
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.